Evidence supporting the use of: Cannabigerolic acid
For the health condition: Psoriasis

Links: Go back one page, Tool main page, Ingredients list, Health conditions list, Body systems list

Synopsis

Source of validity: Scientific
Rating (out of 5): 2

Cannabigerolic acid (CBGA) is a precursor cannabinoid found in Cannabis sativa. Recent scientific research has begun to explore its therapeutic potential, including for skin disorders such as psoriasis. Laboratory studies have suggested that CBGA and other cannabinoids may exert anti-inflammatory effects by interacting with the endocannabinoid system, particularly through the modulation of CB1 and CB2 receptors, which are present in skin cells. In vitro experiments have demonstrated that CBGA can inhibit the proliferation of keratinocytes—the overproduction of which is a hallmark of psoriasis. Additionally, CBGA has shown the ability to reduce the production of pro-inflammatory cytokines, which play a key role in the pathogenesis of psoriasis. However, it is important to note that the bulk of this evidence comes from preclinical studies, including cell culture and animal models. There are currently no published clinical trials directly evaluating the efficacy or safety of CBGA in human patients with psoriasis. While the mechanistic data are promising and provide a scientific rationale for further exploration, clinical validation is lacking. Therefore, the use of CBGA for psoriasis is currently supported by preliminary scientific evidence, but not by robust clinical data or traditional use.

More about Cannabigerolic acid
More about Psoriasis

Other health conditions supported by Cannabigerolic acid

Acne
Arthritis
Inflammation
Inflammatory Bowel Disorders
Psoriasis

Products containing Cannabigerolic acid

We currently have no products on Vitabase that contain this ingredient.